SRF and breast carcinoma: Through its potential dual inhibitory effect on PI3K and mitogen-activated protein kinase (MAPK) pathway components, such as AKT2, serum response factor (SRF), guanine nucleotide binding protein subunit alpha 12 (GNA12), and glycogen synthase 1 (GYS1), miR564 mechanistically suppresses the progression of breast cancer (50).